GlaxoSmithKline Infringes Antibody Patent: Genentech

By Eric Hornbeck

Law360, New York (March 11, 2010, 4:46 PM ET) -- Genentech Inc. has fired back in a suit brought by GlaxoSmithKline PLC seeking to invalidate one of the biotechnology company's antibody patents, insisting that the drugmaker has committed infringement through the sale of cancer treatment Arzerra.

Genentech filed its response and counterclaims Wednesday in the U.S. District Court for the Northern District of California in a declaratory judgment suit brought by GSK that contends the patent-in-suit is invalid, unenforceable and not infringed by Arzerra.

San Fransisco-based Genentech also filed a motion seeking a transfer of the...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles